By Dr. Pavithra Thamizharasan
A decade ago, if someone had told us that a single medication could significantly lower blood sugar, help patients lose substantial weight, reduce the risk of heart disease, and potentially protect the kidneys, it would have sounded too good to be true. Today, that future has become a reality.
India is often referred to as the diabetes capital of the world, but another epidemic has been silently growing alongside it—obesity. Together, these two conditions form what experts now call “diabesity,” a term that reflects the close relationship between excess body weight and type 2 diabetes. Obesity is one of the strongest drivers of insulin resistance, while diabetes itself can make weight management increasingly difficult, trapping patients in a cycle that is often frustrating and emotionally exhausting.
For years, the advice was simple: “Eat less and exercise more.” While lifestyle modification remains the cornerstone of treatment, we now understand that obesity is not merely a result of poor willpower. It is a complex, chronic disease influenced by genetics, hormones, metabolism, gut signaling and environmental factors. Treating obesity, therefore, requires more than determination, it requires science.
This is where the newest generation of medications has transformed diabetes care.
Among them, semaglutide and tirzepatide have emerged as true game changers. Rather than simply lowering blood glucose, these medications target the body’s natural appetite and metabolic pathways. They help patients feel fuller for longer, reduce food cravings, slow stomach emptying and improve insulin action, enabling the body to regulate blood sugar more effectively while promoting sustained weight loss.
Semaglutide, a GLP-1 receptor agonist, has already changed the treatment landscape worldwide. It offers excellent blood sugar control while producing meaningful weight reduction. More importantly, studies have shown that it can lower the risk of cardiovascular events in people with type 2 diabetes and established heart disease. For many patients, this means treating diabetes is no longer just about lowering HbA1c—it is also about protecting the heart, kidneys and overall health.
Building on this success is tirzepatide, the first medication to activate both GIP and GLP-1 receptors. By harnessing two naturally occurring gut hormones instead of one, tirzepatide has demonstrated even greater improvements in weight loss and glycaemic control in many clinical trials. Some patients have achieved weight reductions approaching those seen after bariatric surgery, while simultaneously improving blood pressure, cholesterol levels and fatty liver disease. These advances have generated unprecedented excitement in the medical community. For the first time, we are treating the root causes of metabolic disease rather than merely managing its consequences.
However, excitement must be balanced with responsibility.
Social media has popularised these injections as “weight-loss miracles,” leading many individuals without medical indications to seek them for cosmetic purposes. This trend is concerning. These are prescription medications intended for carefully selected patients after a comprehensive medical evaluation. They require gradual dose escalation, monitoring for side effects and regular follow-up with a qualified physician. Like all medicines, they are not free from adverse effects. Nausea, vomiting, constipation, diarrhoea and abdominal discomfort are among the common side effects, especially during dose escalation. They are not appropriate for everyone, and self-medication can be harmful.
Equally important is understanding that these medications are partners—not substitutes—for a healthy lifestyle. Long-term success still depends on balanced nutrition, regular physical activity, adequate sleep, stress management and resistance training to preserve muscle mass during weight loss. Medication alone cannot build lifelong health.
The encouraging news for Indian patients is that access to these therapies is steadily improving. With the introduction of newer formulations and increasing availability, more eligible patients may benefit from these remarkable advances under appropriate medical supervision.
Yet, while medications continue to evolve, one principle remains unchanged: prevention is always better than cure. Healthy eating habits established in childhood, regular exercise, early screening for diabetes, adequate sleep and maintaining a healthy weight remain the most effective tools in preventing metabolic disease. As a diabetologist, I have witnessed firsthand the emotional burden carried by individuals living with obesity and diabetes. Many have struggled for years despite sincere efforts. For them, these newer therapies represent something far more valuable than weight loss; they represent hope. Hope of reversing disease progression, reducing lifelong complications, improving confidence and reclaiming a healthier future.
Medicine is entering an era where we no longer ask whether obesity should be treated as a disease, we ask how early we should intervene to prevent lifelong complications. Semaglutide and tirzepatide are not miracle drugs, but they are among the most significant breakthroughs in metabolic medicine in recent decades.
The battle against diabesity is far from over, but for the first time, we have powerful tools that allow us to move beyond simply controlling disease to changing its trajectory. Used wisely, alongside healthy lifestyle choices and medical guidance, these therapies have the potential to transform millions of lives.
The future of diabetes care has arrived—and it is giving patients something they have long deserved: not just better numbers, but a better quality of life.
Dr. Pavithra Thamizharasan is a Senior Consultant Physician & Diabetologist at Iswarya Hospital, Chennai